Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Tadić, André ^a   Wagner, Stefanie ^a   Gorbulev, Stanislav ^a   Dahmen, Norbert ^a,b   Hiemke, Christoph ^a   Braus, Dieter F ^c   Lieb, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Clinic for Psychiatry and Psychotherapy   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; PLACEBO;

ARTICLE; CONTROLLED STUDY; DECISION MAKING; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RESPONSE; GENETIC MARKER; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 12; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; EXECUTIVE FUNCTION; FEMALE; HEALTH STATUS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICS;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; EXECUTIVE FUNCTION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 78951490048     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-16     Document Type: Article

References (64)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martínez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacín C, Romera B, Taub N, Vollebergh WA. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica 2004, 109(Suppl. 420):21-27.
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, . National Comorbidity Survey Replication The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105. 10.1001/jama.289.23.3095, 12813115, National Comorbidity Survey Replication.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442. 10.1371/journal.pmed.0030442, 1664601, 17132052.
4. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. Journal of Mental Health Policy Econ 2006, 9:87-98.
5. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000?. Journal of Clinical Psychiatry 2003, 64:1465-1475. 10.4088/JCP.v64n1211, 14728109.
6. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008, 358:252-260. 10.1056/NEJMsa065779, 18199864.
7. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5:45.
8. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303:47-53. 10.1001/jama.2009.1943, 20051569.
9. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Report 2007, 9:449-459.
10. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 1984, 41:782-786.
11. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Archives of General Psychiatry 1987, 44:259-264.
12. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression-Langfassung. 2009, http://www.versorgungsleitlinien.de, http://www.awmf-leitlinien.de. 1. Auflage 2009. DGPPN, ÄZQ, AWMF-Berlin, Düsseldorf 2009. Internet, DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression., http://www.dgppn.de
13. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ. WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. The World Journal of Biological Psychiatry 2007, 8:67-104. 10.1080/15622970701227829, 17455102.
14. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000, 157(Suppl. 4):1-45. American Psychiatric Association.
15. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 2000, 157:1423-1428. 10.1176/appi.ajp.157.9.1423, 10964858.
16. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004, 29:566-579. 10.1038/sj.npp.1300341, 14627997.
17. Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Journal of Affective Disorders 2009, 115:439-449. 10.1016/j.jad.2008.10.011, 19027961.
18. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, Dose T, Wollweber B, Spieler D, Messer T, Lutz R, Kunzel H, Bierner T, Pollmacher T, Pfister H, Nickel T, Sonntag A, Uhr M, Ising M, Holsboer F, Lucae S. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients. Findings from the Munich Antidepressant Response Signature (MARS) project. Journal of Psychiatric Research 2008, 43:215-229. 10.1016/j.jpsychires.2008.05.002, 18586274.
19. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Journal of Clinical Psychopharmacology 2006, 26:56-60. 10.1097/01.jcp.0000195042.62724.76, 16415707.
20. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry 2005, 66:148-158. 10.4088/JCP.v66n0201, 15704999.
21. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Archives of General Psychiatry 2006, 63:1217-1223. 10.1001/archpsyc.63.11.1217, 2211759, 17088502.
22. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. Journal of Clinical Psychiatry 2007, 68:1195-1205. 10.4088/JCP.v68n0805, 17854243.
23. Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Journal of Clinical Psychiatry 2003, 64:413-420. 10.4088/JCP.v64n0410, 12716243.
24. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement as a predictor of treatment outcome in patients with major depressive disorder: Why the first 2 weeks really matter-evidence from 6,562 patients. Journal of Clinical Psychiatry 2009, 70:344-353. 10.4088/JCP.07m03780, 19254516.
25. Tadić A, Helmreich I, Mergl R, Hautzinger M, Henkel V, Hegerl U. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. Journal of Affective Disorders 2010, 120:86-93.
26. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm fort he prediction of antidepressant treatment response. Dialogues in Clinical Neuroscience 2009, 11:435-446.
27. Mössner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Müller N, Fallgatter AJ, Riederer P. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 2007, 8:141-174.
28. Holsboer F. How can we realize the promise of personalized antidepressant medicines?. Nature Reviews Neuroscience 2008, 9:638-646. 10.1038/nrn2453, 18628772.
29. Domenici E, Wille' DR, Tozzi F, Prokopenko I, Miller S, McKeown S, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton F, Merlo-Pich E, Alexander RC, Muglia P. Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections. PLoS ONE 2010, 5:e9166. 10.1371/journal.pone.0009166, 2820097, 20161799.
30. Beblo T, Herrmann M. Neuropsychologische Defizite bei depressiven Störungen. Fortschritt Neurologie Psychiatrie 2000, 68:1-11.
31. Beblo T. Neuropsychologie affektiver Störungen. 2004, Neuropsychologie psychischer Störungen. Heidelberg: Springer Verlag, Lautenbacher S, Gauggel S (Hrsg.).
32. Fossati P, Ergis AM, Allilaire JF. Executive functioning in unipolar depression: a review. Encephalopathy 2005, 28:97-107.
33. Sobin C, Sackeim HA. Psychomotor symptoms of depression. American Journal of Psychiatry 1997, 154:4-17.
34. Christensen H, Griffiths K, Mackinnon A, Jacomb P. A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. Journal of the International Neuropsychological Society 1997, 3:631-651.
35. Veiel HO. A preliminary profile of neuropsychological deficits associated with major depression. Journal of Clinical and Experimenal Neuropsychology 1997, 19:587-603.
36. Savard RJ, Rey AC, Post RM. Halstead-Reitan Category Test in bipolar and unipolar affective disorders. Relationship to age and phase of illness. Journal of Nervous and Mental Disease 1980, 168:297-304. 10.1097/00005053-198005000-00010, 7365494.
37. Beblo T, Baumann B, Bogerts B, Wallesch C, Herrmann M. Neuropsychological Correlates of Major Depression: A Short-term Follow-up. Cognitive Neuropsychiatry 1999, 4:333-341.
38. Potter GC, Kittinger JD, Wagner HR, Steffens DC, Krishnan RR. Prefrontal neuropsychological predictors of treatment remission in late life depression. Neuropsychopharmacology 2004, 29:2266-2271. 10.1038/sj.npp.1300551, 15340392.
39. De GM, Nolen WA, Huijsman AM, Bouvy PF. Lateralized neuropsychological functioning in depressive patients before and after drug therapy. Biological Psychiatry 1996, 40:1282-1287. 10.1016/0006-3223(95)00654-0, 8959293.
40. Paelecke-Habermann Y, Pohl J, Leplow B. Attention and executive functions in remitted major depression patients. Journal of Affective Disorders 2005, 89:125-135. 10.1016/j.jad.2005.09.006, 16324752.
41. Weiland-Fiedler P, Erickson K, Waldeck T, Luckenbaugh DA, Pike D, Bonne O, Charney DS, Neumeister A. Evidence for continuing neuropsychological impairments in depression. Journal of Affective Disorders 2004, 82:253-258. 10.1016/j.jad.2003.10.009, 15488254.
42. Nakano Y, Baba H, Maeshima H, Kitajima A, Sakai Y, Baba K, Suzuki T, Mimura M, Arai H. Executive dysfunction in medicated, remitted state of major depression. Journal of Affective Disorders 2008, 111:46-51. 10.1016/j.jad.2008.01.027, 18304646.
43. Neu P, Bajbouj M, Schilling A, Godemann F, Berman RM, Schlattmann P. Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyper intensities. Journal of Psychiatric Research 2005, 39:129-135. 10.1016/j.jpsychires.2004.06.004, 15589560.
44. Paradiso S, Lamberty GJ, Garvey MJ, Robinson RG. Cognitive impairment in the euthymic phase of chronic unipolar depression. Journal of Nervous and Mental Disease 1997, 185:748-754. 10.1097/00005053-199712000-00005, 9442186.
45. Wong JL, Wetterneck C, Klein A. Effects of depressed mood on verbal memory performance versus self-reports of cognitive difficulties. International Journal of Rehabilitation and Health 2000, 5:85-97.
46. Gorlyn M, Keilp JG, Grunebaum MF, Taylor BP, Oquendo MA, Bruder GE, Stewart JW, Zalsman G, Mann JJ. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. Journal of Neural Transmission 2008, 115:1213-1219. 10.1007/s00702-008-0084-x, 18629432.
47. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. Regional metabolic effects of Fluoxetine in Major Depression: Serial changes and relationship to clinical response. Biological Psychiatry 2000, 48:830-843. 10.1016/S0006-3223(00)01036-2, 11063978.
48. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. British Medical Bulletin 2003, 65:193-207. 10.1093/bmb/65.1.193, 12697626.
49. Tadić A, Gorbulev S, Dahmen N, Hiemke C, Braus DF, Röschke J, van Calker D, Wachtlin D, Kronfeld K, Gorbauch T, Seibert-Grafe M, Lieb K, . EMC Study Group Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder-the EMC trial. Trials 2010, 11:21. 2837649, 20187947, EMC Study Group.
50. Wittchen HU, Weigel A, Pfister H. DIA-X-Diagnostisches Expertensystem 1996, Frankfurt: Swets Test Services.
51. Shehaan DV, Lecrubier Y. M.I.N.I. International Neuropsychiatric Interview 1998, USA Tampa.
52. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2004, American Psychiatric Press: Washington DC, 4, American Psychiatric Association.
53. Dilling H, Mombour W, Schmidt MH. International Classification of Mental and Behavioral Disorders. ICD-10 chapter V 2010, Huber: Bern, Switzerland.
54. Wittchen HU, Zaudig M, Fydrich T. SKID-I/-II: Strukturiertes klinisches Interview für DSM-IV 1996, Hogrefe: Göttingen.
55. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, Psychiatry 1960, 23:56-62.
56. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi HM. The inventory of Depressive Symptomatology (IDS). Psychological Medicine 1986, 26:477-486.
57. Bullinger M, Kirchberger I. Fragebogen zum Gesundheitszustand - SF 12 1998, Göttingen: Hogrefe Verlag.
58. Lehrl S. 1969, Erlangen: Perimed Fachbuch Verlagsgesellschaft mbH, Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B).
59. Aschenbrenner S, Tucha O, Lange KW. RWT. Regensburger Wortflüssigkeits-Test 2000, Göttingen: Hogrefe.
60. Reitan RM. Trail Making Test - Manual for Administration and Scoring 1979, Tucson: Reitan Neuropsychology Laboratory.
61. Werheid K, Hoppe C, Thöne A, Müller U, Müngersdorf M, von Cramon DY. The Adaptive Digit Ordering Test clinical application, reliability and validity of a verbal working memory test. Archives of Clinical Neuropsychology 2002, 17:547-565.
62. Ruff R. Ruff Figural Fluency Test (RFFT) 1988, San Diego: Neuropsychological resources.
63. Müller MJ, Dragicevic A. Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. Journal of Affective Disorders 2003, 77:65-69.
64. Wagner S, Baskaya T, Lieb K, Tadic A. Standardized rater training for the Hamilton Depression Scale (HAMD17) and the Inventory of Depressive Symptoms (IDS30CR). Psychopathology 2011, 44:68-70. 10.1159/000318162, 21072002.